Jubilant Ingrevia Reports Strong Start to FY2027 with Revenue Reaching ₹1,300 Crore; Highlights Growth in Specialty Chemicals and Nutrition

Jubilant Ingrevia Reports Strong Start to FY2027 with Revenue Reaching ₹1,300 Crore; Highlights Growth in Specialty Chemicals and Nutrition​

Jubilant Ingrevia Limited announced its financial results for the quarter ended June 30, 2026, reporting robust growth across all key segments. The company saw Total Revenue climb to ₹1,300 crore, marking a 25% increase year-over-year (YoY), while Net Profit rose by 41% YoY.

The consolidated results reflected disciplined execution and strong demand dynamics across the global chemical industry.

Q1'FY27 Consolidated Financial Performance​

For the quarter ended June 30, 2026, Jubilant Ingrevia posted significant growth in profitability metrics:

Segmental Performance Drives Growth​

The company’s performance was segmented across three major business units: Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates.

Specialty Chemicals:
The Specialty Chemicals segment recorded revenue of ₹533 crore for Q1'FY27, growing 11% YoY and 3% QoQ. This segment remains a primary growth driver, with its EBITDA reaching ₹139 crore (at 26% margin). Business developments include steady volumes in Pyridine & Picolines and expanding momentum in Fine Chemicals across cosmetics and industrial applications. In CDMO, the company saw strong customer traction from pharmaceuticals (Pharma) and agriculture (Agro), supported by US and Europe roadshows leading to a threefold expansion in the pipeline with innovators and Tier-1 CDMOs.

Nutrition & Health Solutions:
The Nutrition segment reported revenue of ₹243 crore for Q1'FY27, registering 36% YoY growth and a 6% QoQ increase. The EBITDA reached ₹36 crore (at 15% margin). Human Nutrition saw strong growth in Niacinamide volumes, while the Animal Nutrition business benefited from significant price improvements across its product portfolio.

Chemical Intermediates:
The Chemical Intermediates segment showed a considerable rebound, achieving revenue of ₹524 crore—a 38% YoY increase and 21% QoQ rise. EBITDA for this segment was reported at ₹57 crore, up 240% YoY and 163% QoQ, driven by improved realizations and strong demand in key products like Acetic Anhydride and Ethyl Acetate.

Management Commentary and Future Outlook​

Speaking on the performance, Mr. Shyam S Bhartia, Chairman, and Mr. Hari S Bhartia, Co-Chairman, noted that the results reflect a strong business model execution despite continued geopolitical uncertainties in the Middle East. They highlighted the resilience of demand across the chemical industry and robust growth in pharmaceuticals and nutrition markets.

Mr. Deepak Jain, CEO and MD, stated that operational agility and diversified sourcing enabled effective cost pass-through during challenging periods. He confirmed that the company’s outlook for FY2027 is positive, with anticipated growth led by Specialty Chemicals and Nutrition. The company also indicated that its new Multi-Purpose Plant remains on track for commissioning by the end of the current calendar year, which will strengthen its CDMO and Fine Chemicals roadmap.

The company also reported multiple operational milestones in Q1'FY27, including successfully clearing over 20 customer quality and EHS audits, achieving a Distinction at the British Safety Council International Safety Awards for its Gajraula facility, and completing the integration of Remidex Pharma.

JUBLINGREA Stock Price Movement​

Jubilant Ingrevia Limited shares today slipped by 1.68% to settle at ₹743.75 in the closed market. The equity traded within an intraday range, having hit a low of ₹714.05 during the session.